Country: Canada
Language: English
Source: Health Canada
FLUOXETINE (FLUOXETINE HYDROCHLORIDE)
APOTEX INC
N06AB03
FLUOXETINE
10MG
CAPSULE
FLUOXETINE (FLUOXETINE HYDROCHLORIDE) 10MG
ORAL
100
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0116847003; AHFS:
APPROVED
2021-01-19
_PR_ _FLUOXETINE (fluoxetine hydrochloride)_ _Page 1 of 56 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR FLUOXETINE Fluoxetine Hydrochloride Capsules 10 mg and 20 mg fluoxetine (as fluoxetine hydrochloride), Oral USP PR FLUOXETINE Fluoxetine Oral Solution 20 mg/5 mL fluoxetine (as fluoxetine hydrochloride) USP Antidepressant/ Antiobsessional/ Antibulimic APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: January 19, 2021 Date of Revision: March 18, 2022 Submission Control number: 257282 _PR_ _FLUOXETINE (fluoxetine hydrochloride)_ _Page 2 of 56 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 03/2022 7 Warnings and Precautions, 7.1.1 Pregnant Women 03/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ....................................................................................................................... 4 1.2 Geriatrics ....................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 6 4.1 Dosing Considerations ................................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment .............................................. Read the complete document